For us, this report is a conscious management step within the framework of transformation into a modern biotechnology company operating in international markets and planning development in the long term.
“This report is the first ESG report of Enzym Group. We prepared it not because Ukrainian regulation requires it, but because we consider ESG to be a necessary basis for managing a modern biotechnology company,” says Andriy Tsegelyk, CEO of Enzym Group.
The company is at the stage of deep transformation – from traditional production to an integrated biotechnology business model with a focus on innovation, R&D and international partnership. In these conditions, the issue of business impact on the environment, people and communities becomes part of daily management, and not a separate social initiative.
“For us, ESG is not a separate project or formal reporting. It is a business management tool that is integrated into the strategy, operational processes and corporate governance system,” emphasizes Andriy Tsegelyk.
The preparation of the report was preceded by systematic work. In 2024, Enzym Group initiated an independent audit of social projects and business processes with the participation of the expert organization CSR Ukraine. The audit covered the industry context, the level of integration of ESG into the company's key processes, stakeholder expectations and potential risks. In parallel, the team underwent training in ESG practices and regulatory requirements to avoid a formal approach "for reporting".
Based on the audit results, the company approved a five-year ESG strategy with clear goals, indicators and a phased roadmap. A cross-functional working group with the participation of management is involved in its implementation, which is responsible for integrating the principles of sustainable development into strategic planning and operational activities.
“We consciously focus on European and global standards, even in the absence of mandatory requirements, since it is this approach that creates trust, increases business sustainability and opens up opportunities for long-term development,” says the CEO of Enzym Group.
Enzym Group’s ESG strategy covers all three components – Environmental, Social and Governance. Among the key challenges that the company responds to through the ESG approach are the high energy intensity of biotechnological production, dependence on energy resources, the need to reduce the environmental footprint, develop human capital and increase the transparency of corporate governance for working in international markets.
The first ESG report records the start of this path – approaches, first results and areas of development that require further systematic work. It reflects not only achievements, but also challenges that the company is working with in conditions of war, regulatory changes and increasing requirements from partners and investors.
“In the report, we talk not only about achievements, but also about areas of development that require systematic work. We are convinced: responsible business creates value not only for the company – for the team, for communities and for society as a whole,” Andriy Tsegelyk summarizes.
